Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 05, 2020
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 02, 2020
Dynacure Announces EUR50M ($55M) Series C Financing
Feb 27, 2020
Ionis Pharmaceuticals to present at upcoming investor conferences
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Dec 24, 2019
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 10, 2019
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Sep 17, 2019
Positive preliminary results from ATL1102 for DMD Phase II trial
Jul 01, 2019
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jun 18, 2019
Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
Mar 07, 2019
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Jan 04, 2019
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
Jan 02, 2019
Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Nov 27, 2018
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
Oct 23, 2018
Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science
Oct 22, 2018
Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology